PIK3CA and breast carcinoma: Taken together, we have developed a model to evaluate the use of PI3K and endocrine therapies in aromatase inhibitor sensitive and refractory ER+ breast cancer cells and demonstrate the activity of a novel inhibitor of PI3K in this indication.